Neuropathy "The Painful Enigma"

Inflammatory reactions in the central nervous system (CNS) are currently known to be associated with many neurological disorders. In neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), there is considerable penetration of different leukocyte subsets into the CNS or there is severe activation of microglial cells which increases many inflammatory mediators in the CNS. In acute CNS disorders, including delayed corrosion associated with vasospasm after subarachnoid hemorrhage (SAH), ischemic stroke, spontaneous intracerebral hemorrhage (ICH), and traumatic brain injury (TBI), current evidence from a variety of research studies reveal that inflammation may be a possible target for treatment. Inflammation is becoming a promising region of research study for new treatments.

 

To speed up the process of translating this information to clinical applications, a number of significant problems have to be addressed as their capacity to continuously identify characteristic cerebral deficits in people with neurodegenerative diseases, the connections of brain injuries to clinical symptoms and genetic diagnosis as well as the level to which the harm respond to various treatment approaches. In this article, findings that address some of these problems are reported by several researchers.